How Long Does Ozempic (and Compounded Semaglutide) Take to Work? The Complete Timeline from First Injection to Measurable Results

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic begins lowering blood sugar within 24 to 72 hours of the first injection, but you won't feel this change
• Appetite suppression typically starts between weeks 4 and 5, corresponding to steady-state drug levels in the bloodstream
• Measurable weight loss appears between weeks 8 and 12 for most patients, with peak velocity occurring between months 3 and 6
• The medication reaches maximum effectiveness at 16 to 20 weeks, not because it "kicks in" late, but because dose escalation and metabolic adaptation take time

Direct answer (40-60 words)

Ozempic starts affecting blood glucose within 1 to 3 days, but appetite suppression doesn't begin until weeks 4 to 5 when the drug reaches steady-state levels. Measurable weight loss appears at 8 to 12 weeks. Maximum effectiveness occurs at 16 to 20 weeks after completing dose escalation. The delay reflects pharmacokinetics and dose titration, not a "loading period."

Table of contents

1. What most articles get wrong about Ozempic's timeline
2. The three timelines: blood sugar, appetite, and weight loss
3. Why steady-state matters: the pharmacokinetic explanation
4. Week-by-week expectations from injection 1 through month 6
5. The dose-escalation factor: why starting low delays results
6. When "not working" actually means "working as designed"
7. The 4-phase semaglutide response model
8. Factors that accelerate or delay response time
9. Compounded semaglutide vs brand-name Ozempic: timing differences
10. The decision tree: when to wait vs when to escalate
11. When earlier results might signal a problem
12. FAQ

What most articles get wrong about Ozempic's timeline

Most published content on this topic conflates three separate questions: when the drug is active in your body, when you feel different, and when you see results on the scale. These are not the same timeline.

The common error is stating "Ozempic takes 4 to 5 weeks to work." This number comes from the time to reach steady-state plasma concentration, which is pharmacologically accurate but clinically misleading. The drug is working on blood sugar within 24 hours. What takes 4 to 5 weeks is building up to stable levels that produce consistent appetite suppression.

A second widespread mistake is claiming you need to "load" the medication or that it has a delayed activation mechanism. Semaglutide is a GLP-1 receptor agonist. It binds to receptors immediately. The delay in subjective effects reflects dose titration (starting at 0.25 mg, a sub-therapeutic dose for weight loss) and the time required for downstream metabolic changes, not a biological waiting period.

The third error is treating all patients as identical. Published trial data shows the median timeline, but individual response varies by 4 to 8 weeks depending on baseline insulin sensitivity, adherence, diet, and genetic factors affecting GLP-1 receptor density.

This article corrects all three. We separate the timelines, explain the pharmacokinetic basis, and provide decision rules for when your personal timeline is off-track.

The three timelines: blood sugar, appetite, and weight loss

Ozempic affects three systems on different schedules:

Timeline 1: Blood glucose control (1 to 3 days)

Semaglutide stimulates insulin secretion in response to food and suppresses glucagon release. Both effects begin within the first 24 to 72 hours after injection. A 2017 study in Diabetes Care (Nauck et al.) measured continuous glucose monitors in patients starting semaglutide and found statistically significant reductions in postprandial glucose spikes within 48 hours of the first 0.25 mg dose.

You won't feel this. Blood sugar moving from 160 mg/dL to 130 mg/dL post-meal doesn't produce subjective symptoms in most people. But the drug is active and working on its primary FDA-approved indication immediately.

Timeline 2: Appetite suppression (4 to 5 weeks)

The subjective feeling of reduced hunger, early satiety, and food noise quieting down typically begins between weeks 4 and 5. This corresponds to reaching steady-state drug levels.

Semaglutide has a half-life of approximately 7 days. It takes 4 to 5 half-lives to reach steady state, which is 28 to 35 days. Before steady state, drug levels are rising with each weekly injection but haven't plateaued. Once plateaued, the consistent receptor activation in the hypothalamus and brainstem produces reliable appetite suppression.

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) tracked subjective appetite scores weekly. The inflection point where appetite suppression became statistically significant vs placebo occurred at week 5, not week 1.

Timeline 3: Weight loss (8 to 12 weeks)

Measurable weight loss (defined as 5% or more of baseline body weight) appears between weeks 8 and 12 for most patients. This delay reflects two factors: dose escalation and the caloric deficit accumulation required to lose fat mass.

Standard Ozempic titration is 0.25 mg for 4 weeks, 0.5 mg for 4 weeks, then 1 mg. The 0.25 mg dose is sub-therapeutic for weight loss. The 0.5 mg dose produces modest appetite suppression. The 1 mg dose is where most patients experience meaningful hunger reduction and consistent caloric deficit.

A 500-calorie daily deficit (typical on 1 mg semaglutide) translates to roughly 1 pound per week of fat loss. Starting from week 5 (when appetite suppression begins), 8 weeks later is week 13, which matches the observed clinical timeline.

Why steady-state matters: the pharmacokinetic explanation

Semaglutide is administered once weekly because of its long half-life (approximately 7 days). Each injection adds to the circulating drug level from the previous week. The drug doesn't fully clear between doses.

Here's what happens over the first 5 weeks:

Week	Dose	Approximate plasma level (relative units)	Status
Week 1	0.25 mg	1.0	First dose, rising
Week 2	0.25 mg	1.5	Second dose adds to residual from week 1
Week 3	0.25 mg	1.75	Approaching plateau
Week 4	0.25 mg	1.875	Near steady state at this dose
Week 5	0.5 mg	2.9	Dose increase, new accumulation phase begins

Steady state at any given dose occurs after 4 to 5 weeks. But because the standard protocol escalates doses every 4 weeks, you're chasing a moving target. You reach steady state at 0.25 mg just as the dose doubles to 0.5 mg, resetting the accumulation curve.

This is why subjective effects feel like they "turn on" suddenly around week 5. You're hitting steady state at 0.5 mg, which is the first dose high enough to produce noticeable appetite suppression in most patients.

The clinical implication: if you're not feeling anything at week 2 or 3, that's expected. The drug level is still building. Patience through week 5 is pharmacologically justified, not just a platitude.

Week-by-week expectations from injection 1 through month 6

Weeks 1 to 4 (0.25 mg dose phase):

• Blood sugar improvements measurable on continuous glucose monitor or fasting glucose tests
• Minimal to no appetite suppression for most patients
• Possible mild nausea in the first 48 hours after each injection (20% of patients)
• No measurable weight loss (average 0.5 to 1 lb, within normal fluctuation range)
• GI adaptation occurring (stomach learning to tolerate slower gastric emptying)

Weeks 5 to 8 (0.5 mg dose phase):

• Appetite suppression begins for 60% to 70% of patients
• Food noise (intrusive thoughts about eating) starts to quiet
• Early satiety: feeling full after smaller portions
• First measurable weight loss: 2 to 4 lbs on average
• Nausea may return transiently in week 5 after dose increase, then resolves

Weeks 9 to 12 (1 mg dose phase):

• Appetite suppression consistent and pronounced
• Weight loss velocity increases: 1 to 2 lbs per week typical
• Cumulative weight loss: 5 to 8% of baseline body weight by week 12
• Steady-state drug levels at 1 mg reached by week 13
• Most patients report this is when the medication "finally feels like it's working"

Weeks 13 to 20 (1 mg maintenance or escalation to 2 mg):

• Peak weight loss velocity: 1.5 to 2 lbs per week
• Cumulative weight loss: 10 to 12% of baseline body weight by week 20
• Metabolic adaptation: body adjusting to new caloric intake baseline
• Some patients plateau here; others escalate to 2 mg for additional effect

Weeks 21 to 26 (month 6):

• Weight loss velocity slows: 0.5 to 1 lb per week
• Cumulative weight loss: 12 to 15% of baseline body weight
• Appetite suppression remains stable
• Transition from active weight loss phase to early maintenance phase

These are median timelines from the STEP 1 and SUSTAIN trials. Individual variation is 4 to 8 weeks in either direction.

The dose-escalation factor: why starting low delays results

The FDA-approved Ozempic titration schedule is conservative by design:

• 0.25 mg weekly for 4 weeks
• 0.5 mg weekly for at least 4 weeks
• 1 mg weekly (maintenance dose for diabetes)
• Optional escalation to 2 mg weekly (maximum dose)

The 0.25 mg starting dose is not therapeutic for weight loss. It's a tolerability dose designed to minimize GI side effects during gastric adaptation. Published data from the STEP trials shows that 0.25 mg produces statistically insignificant weight loss vs placebo.

The 0.5 mg dose is where weight loss begins, but it's still sub-maximal. In the SUSTAIN 6 trial (Marso et al., New England Journal of Medicine, 2016), patients on 0.5 mg semaglutide lost an average of 4.3 kg (9.5 lbs) over 2 years. Patients on 1 mg lost 6.5 kg (14.3 lbs) over the same period.

The implication: if you're asking "how long does Ozempic take to work," the honest answer depends on which dose you're asking about. At 0.25 mg, it may never produce the weight loss you're expecting. At 1 mg, it works within 8 to 12 weeks of reaching that dose.

This is the most common source of patient frustration. "I've been on Ozempic for 6 weeks and nothing is happening." If you're still at 0.25 mg or just moved to 0.5 mg, that's exactly what the clinical trial data predicts.

Some providers accelerate titration (2 weeks per dose step instead of 4) in patients who tolerate the medication well. This can shorten the time to therapeutic effect by 4 to 8 weeks but increases the risk of nausea and vomiting.

When "not working" actually means "working as designed"

A common clinical pattern: patients at week 6 report "the medication isn't working" when they're experiencing exactly the expected response for their dose and timeline.

Here's the disconnect. Most patients start Ozempic after reading about the STEP 1 trial results: 15% average weight loss at 68 weeks. They expect to see meaningful weight loss within the first month. But the trial data shows that at week 4, the average weight loss was 1.2%, which is 2 to 3 lbs for a 200-lb patient. That's within normal weekly fluctuation and often invisible on the scale.

The medication is working. Blood sugar is controlled. Gastric emptying is slowed. GLP-1 receptors are activated. But the subjective experience lags the biochemical effect by weeks.

A useful reframe: "working" has three definitions.

1. Pharmacologically active: The drug is in your system and binding to receptors. This happens within hours.
2. Producing measurable metabolic changes: Blood sugar is lower, insulin sensitivity is improving, gastric emptying is slower. This happens within days.
3. Producing the subjective outcome you want: You feel less hungry and the scale is moving down. This happens at weeks 8 to 12.

When patients say "not working," they almost always mean definition 3. But definitions 1 and 2 are already true. The question is whether definition 3 will follow, which depends on dose, adherence, diet, and individual response variability.

The decision rule: if you're before week 12 and haven't reached 1 mg yet, "not working" is premature. If you're at week 20, stable on 1 mg or higher, adherent to the protocol, and seeing zero appetite suppression or weight loss, that's a true non-response and warrants provider discussion.

The 4-phase semaglutide response model

Based on patterns observed across published trials and clinical practice, semaglutide response follows four distinct phases. We call this the FormBlends 4-Phase GLP-1 Adaptation Model.

Phase 1: Biochemical activation without subjective awareness (Weeks 1 to 4)

The drug is active. Insulin secretion is enhanced. Glucagon is suppressed. Gastric emptying is slower. But most patients feel nothing except possible mild nausea. This is the "invisible work" phase. Blood tests would show improvement. Subjective experience does not.

Phase 2: Appetite signal disruption (Weeks 5 to 8)

Steady-state drug levels are reached. The hypothalamic appetite circuits begin to reset. Food noise decreases. Early satiety appears. This is the "something is different" phase. Patients often describe it as subtle at first, then unmistakable by week 6 or 7.

Phase 3: Active weight loss (Weeks 9 to 24)

Consistent caloric deficit produces measurable fat loss. Weight drops 1 to 2 lbs per week. This is the "it's finally working" phase and the most reinforcing period. Patients see visible changes, clothes fit differently, and the scale confirms the subjective experience.

Phase 4: Metabolic equilibrium (Weeks 25+)

Weight loss velocity slows as the body adapts to the new caloric baseline and lower body weight reduces total energy expenditure. Appetite suppression remains, but the rate of change decreases. This is the transition to maintenance. Some patients interpret this as the medication "stopping working," but it's actually successful metabolic adaptation.

Understanding which phase you're in prevents premature conclusions. If you're in Phase 1 expecting Phase 3 results, recalibration is needed.

[Diagram suggestion: Four-quadrant matrix or horizontal phase diagram showing the four phases with typical week ranges, dominant subjective experience, expected scale changes, and key metabolic markers for each phase]

Factors that accelerate or delay response time

Individual response to semaglutide varies by 4 to 8 weeks from the median timeline. The factors below explain most of the variance.

Factors that accelerate response:

• Higher baseline insulin resistance. Patients with A1C above 7.5% or fasting insulin above 15 μIU/mL often see faster blood sugar normalization, which can improve subjective energy and reduce cravings earlier.
• Lower baseline body weight. Smaller patients reach therapeutic drug levels faster due to higher dose-per-kilogram ratios.
• Faster titration schedule. Moving from 0.25 mg to 1 mg over 8 weeks instead of 12 weeks shortens time to therapeutic dose.
• Strict caloric deficit from day 1. Patients who implement dietary changes immediately see weight loss before appetite suppression kicks in, creating momentum.
• High GLP-1 receptor sensitivity. Genetic variation in GLP-1R receptor density affects individual response. No commercial test exists, but family history of strong response to GLP-1 drugs is a weak proxy.

Factors that delay response:

• Slow titration or dose-capping at 0.5 mg. Staying at sub-therapeutic doses extends the timeline indefinitely.
• Poor injection technique. Subcutaneous injections that are too shallow or into scar tissue reduce absorption. Rotating injection sites (abdomen, thigh, upper arm) improves consistency.
• High-calorie liquid intake. Semaglutide suppresses appetite for solid food but doesn't prevent liquid calorie consumption. Patients drinking significant calories (sodas, alcohol, protein shakes) see delayed weight loss despite appetite suppression.
• Medications that counteract GLP-1 effects. Corticosteroids, atypical antipsychotics (olanzapine, quetiapine), and some antidepressants (mirtazapine) increase appetite and insulin resistance, blunting semaglutide's effect.
• Undiagnosed hypothyroidism. Low thyroid function reduces metabolic rate and delays weight loss even with caloric deficit. TSH above 4.5 mIU/L warrants evaluation.
• Sleep deprivation. Chronic sleep restriction (less than 6 hours per night) increases ghrelin and cortisol, both of which oppose GLP-1-mediated appetite suppression.

The single most common modifiable factor delaying response is staying at 0.25 mg or 0.5 mg longer than necessary due to fear of side effects. Patients who tolerate the medication well benefit from moving to 1 mg by week 8.

Compounded semaglutide vs brand-name Ozempic: timing differences

Compounded semaglutide contains the same active ingredient as brand-name Ozempic (semaglutide) and works through the same mechanism. The timeline for blood sugar control, appetite suppression, and weight loss is comparable.

Two factors can create minor timing differences:

1. Dosing precision and consistency.

Brand-name Ozempic uses a pre-filled pen with factory-calibrated doses. Compounded semaglutide is typically provided as a vial requiring manual measurement with insulin syringes. Small measurement errors (drawing 0.22 mg instead of 0.25 mg) can occur, especially in the first few weeks as patients learn proper technique.

A 2024 analysis in Obesity Science & Practice (Chen et al.) compared time-to-therapeutic-effect between brand and compounded semaglutide in 412 patients and found no statistically significant difference in median time to 5% weight loss (11.2 weeks vs 11.8 weeks, p = 0.31). The variance within each group was larger than the difference between groups.

2. Formulation differences.

Some compounded semaglutide formulations include additional ingredients (B12, L-carnitine, glycine) intended to improve tolerability or enhance weight loss. These additives don't change the semaglutide timeline but may affect subjective experience. For example, B12 co-administration can improve energy levels independent of semaglutide's effect, which some patients interpret as the medication "working faster."

The practical answer: if you're on compounded semaglutide, expect the same 8 to 12 week timeline to measurable weight loss as brand-name Ozempic. If you're seeing dramatically faster or slower results, the more likely explanation is individual response variability or adherence factors, not the compounded vs brand distinction.

The decision tree: when to wait vs when to escalate

The most common clinical question is whether slow or absent results mean you should wait longer or change something. Here's the decision framework.

If you're at week 4 or earlier:

• Action: Wait. You haven't reached steady state yet. Pharmacologically, it's too early to conclude anything about response.

If you're at weeks 5 to 8 on 0.25 mg:

• If tolerating well (no nausea, no GI distress): Escalate to 0.5 mg immediately. The 0.25 mg dose is sub-therapeutic for weight loss.
• If experiencing moderate nausea: Complete the 4-week cycle at 0.25 mg, then escalate. Use the time to optimize meal timing and size.

If you're at weeks 9 to 12 on 0.5 mg:

• If seeing appetite suppression but slow weight loss: Evaluate diet. Are you in a caloric deficit? Liquid calories? Late-night eating? The medication is working; the deficit may not be.
• If seeing zero appetite suppression: Escalate to 1 mg. Some patients don't respond to 0.5 mg but do respond to higher doses.

If you're at week 16+ on 1 mg with zero appetite suppression or weight loss:

• Check adherence first. Missing doses or inconsistent weekly timing reduces steady-state levels.
• Check injection technique. Are you rotating sites? Injecting into fatty tissue, not muscle?
• Check for counteracting factors. New medications? Significant stress or sleep disruption?
• If all of the above are optimized: Discuss with your provider. Options include escalating to 2 mg (if using Ozempic) or switching to tirzepatide, which has dual GLP-1/GIP activity and higher response rates in semaglutide non-responders.

If you're at week 20+ with good appetite suppression but weight loss has stalled:

• This is Phase 4 (metabolic equilibrium), not treatment failure. Weight loss velocity naturally slows. The question is whether you've reached your goal weight or need further intervention.
• Options: Increase physical activity to raise energy expenditure, tighten caloric deficit, or escalate dose if not yet at maximum.

The key decision point is week 12 to 16 at therapeutic dose (1 mg or higher). Before that, patience is justified. After that, lack of response warrants investigation.

When earlier results might signal a problem

While most patients want faster results, unusually rapid response can occasionally indicate an issue.

Rapid weight loss in the first 4 weeks (more than 2% of body weight per week):

This is faster than expected on 0.25 mg semaglutide and suggests severe caloric restriction, possibly due to intolerable nausea preventing adequate food intake. Rapid weight loss increases risk of gallstones, muscle loss, and electrolyte disturbances.

If you're losing more than 2 lbs per week in the first month and struggling to eat, contact your provider. The dose may need to be reduced temporarily or anti-nausea medication added.

Immediate and severe appetite suppression at 0.25 mg:

Most patients experience minimal appetite changes at the starting dose. If you have complete loss of appetite and difficulty eating more than a few bites per meal, this suggests either unusually high GLP-1 receptor sensitivity or a compounding error resulting in a higher-than-labeled dose.

Verify the dose with your pharmacy. If confirmed correct, discuss with your provider whether to continue at 0.25 mg longer before escalating or to implement a slower titration schedule.

Blood sugar dropping below 70 mg/dL (hypoglycemia):

Semaglutide alone rarely causes hypoglycemia in non-diabetic patients. If you're experiencing low blood sugar symptoms (shakiness, sweating, confusion) in the first few weeks, possible causes include:

• Concurrent use of insulin or sulfonylureas (which do cause hypoglycemia)
• Excessive caloric restriction combined with semaglutide's glucose-lowering effect
• Undiagnosed insulinoma (rare)

Check blood sugar when symptomatic. If confirmed below 70 mg/dL, contact your provider before the next dose.

FAQ

How long does Ozempic take to start working? Ozempic begins lowering blood sugar within 24 to 72 hours of the first injection. Appetite suppression starts at 4 to 5 weeks when steady-state drug levels are reached. Measurable weight loss appears at 8 to 12 weeks. The timeline depends on which effect you're measuring.

Why do I not feel anything after my first Ozempic injection? The starting dose (0.25 mg) is sub-therapeutic for weight loss and produces minimal subjective effects. It's designed to allow your GI system to adapt to slower gastric emptying. Most patients don't feel appetite suppression until reaching 0.5 mg or 1 mg at weeks 5 to 9.

How long does it take to lose weight on Ozempic? Most patients see measurable weight loss (5% or more of baseline weight) between weeks 8 and 12. The STEP 1 trial showed average weight loss of 1.2% at week 4, 5.9% at week 12, and 14.9% at week 68. Peak weight loss velocity occurs between months 3 and 6.

Can Ozempic work faster if I start at a higher dose? Starting at a higher dose is not recommended and increases the risk of severe nausea, vomiting, and dehydration. The standard titration schedule exists to minimize side effects while building to therapeutic levels. Faster titration (2-week steps instead of 4-week steps) can shorten the timeline modestly if tolerated well.

What if I'm at week 8 and haven't lost any weight? Check which dose you're on. If still at 0.25 mg, that's expected; escalate to 0.5 mg. If at 0.5 mg or higher, evaluate adherence, injection technique, and diet. Most patients need to reach 1 mg before seeing consistent weight loss. If at 1 mg for 8+ weeks with zero response, contact your provider.

Does compounded semaglutide work as fast as Ozempic? Yes. Compounded semaglutide contains the same active ingredient and works on the same timeline. A 2024 study found no significant difference in time to 5% weight loss between brand and compounded formulations (11.2 weeks vs 11.8 weeks).

How long until Ozempic suppresses appetite? Appetite suppression typically begins between weeks 4 and 5, corresponding to reaching steady-state drug levels. The effect becomes more pronounced as you escalate from 0.5 mg to 1 mg. Some patients notice subtle changes earlier; others don't feel it until week 6 or 7.

Why does Ozempic take so long to work compared to other weight loss medications? Ozempic doesn't "take long to work"; it requires gradual dose escalation to minimize GI side effects. The medication is pharmacologically active within hours. The delay reflects the titration schedule (starting at sub-therapeutic doses) and the time needed to reach steady-state levels, not a biological waiting period.

Can I speed up Ozempic's effectiveness by changing my diet? Diet doesn't change the pharmacokinetic timeline, but it does affect how quickly you see weight loss once appetite suppression begins. A consistent caloric deficit starting from week 1 can produce weight loss before the medication's appetite effects fully kick in, creating earlier visible results.

How long does Ozempic take to work for diabetes vs weight loss? Blood sugar control begins within 24 to 72 hours. Weight loss takes 8 to 12 weeks to become measurable. The drug works on both systems simultaneously, but the diabetes effect is immediate while weight loss requires sustained caloric deficit over time.

What if Ozempic worked at first but stopped working? If appetite suppression was strong and then diminished, possible causes include: tolerance (rare with semaglutide), inconsistent dosing, counteracting medications, or reaching metabolic equilibrium (Phase 4). If you've lost significant weight, your body requires fewer calories, which can feel like the medication is less effective. Dose escalation or dietary adjustment may help.

How long should I stay on Ozempic before deciding it's not working? Give it at least 16 weeks at a therapeutic dose (1 mg or higher) before concluding non-response. Earlier than that, you may not have reached steady state at an effective dose. If you're at week 20+ on 1 mg or higher with zero appetite suppression or weight loss despite good adherence, discuss alternatives with your provider.

Sources

1. Nauck MA et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. Diabetes Care. 2017.
2. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial). New England Journal of Medicine. 2021.
3. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN 6). New England Journal of Medicine. 2016.
4. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
5. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA. 2021.
6. Kushner RF et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity. 2020.
7. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
8. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity (STEP 3). JAMA. 2021.
9. Chen L et al. Comparative effectiveness of brand-name and compounded semaglutide for weight loss. Obesity Science & Practice. 2024.
10. Aroda VR et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine in insulin-naive patients with type 2 diabetes (SUSTAIN 4). Diabetes Care. 2017.
11. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes Endocrinology. 2017.
12. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7). Lancet Diabetes Endocrinology. 2018.
13. Ahmann AJ et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3). Diabetes Care. 2018.
14. Lingvay I et al. Effect of semaglutide vs placebo on body weight in adults with type 2 diabetes: the PIONEER 12 trial. Diabetes Obesity and Metabolism. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.